News & Updates

AChEIs and memantine cost-effective, offer improvements in AD
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022 byNatalia Reoutova

A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.

AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022
Platelet function a potential biomarker of Alzheimer’s disease
Platelet function a potential biomarker of Alzheimer’s disease
07 May 2022
One in 10 patients fully recover from consciousness disorders after severe COVID-19
One in 10 patients fully recover from consciousness disorders after severe COVID-19
28 Apr 2022 byTristan Manalac

Among patients who suffer from disorders of consciousness (DoC) after severe COVID-19, around 10 percent can achieve functional independence after 1 year, reports a study presented at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

One in 10 patients fully recover from consciousness disorders after severe COVID-19
28 Apr 2022